HILDEN, Germany & GERMANTOWN, Maryland–(BUSINESS WIRE)–QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its commitment to workplace diversity and gender equality has been recognized through its inclusion in the Human Rights Campaign Foundation’s US LGBTQ+ Corporate Equality Index (CEI) and the Bloomberg Gender-Equality Index ( GEI).
QIAGEN’s U.S. subsidiary was named “Best Workplace for LGBTQ+ Equality” after achieving a perfect score of 100 in the Human Rights Campaign (HRC) Foundation CEI 2022. The IEC 2022 results showcase companies that are helping to advance and promote LGBTQ+-friendly workplace policies in the United States and abroad. Through its programs, HRC seeks to bring about transformational change in the daily lives of lesbian, gay, bisexual, transgender and queer plus (LGBTQ+) people, shedding light on inequalities and deepening public understanding of LGBTQ+ issues. , with a clear focus on transgender advancement and racial justice.
QIAGEN has become one of 418 companies operating across the world in a wide range of industries to join Bloomberg’s GEI 2022, a modified market capitalization-weighted index that aims to track the performance of public companies engaged in transparency in reporting gender data. The index assesses each company’s performance on gender equality by tracking female leadership and talent pool, gender pay and pay equity, cultural inclusiveness, policies to prevent sexual harassment and the company’s efforts to be a pro-women brand.
“Creating a truly diverse and inclusive environment is one of our core values at QIAGEN,” said Stephany Foster, Senior Vice President and Head of Global Human Resources at QIAGEN. “We are committed to developing a culture where all individuals have equal opportunity to succeed – through a comprehensive program designed to drive long-term change across our organization. Recognition by the HRC CEI and Bloomberg GEI validates our commitment to making life improvements possible, not only externally, but also internally for our employees.
QIAGEN has recently reviewed and updated policies and practices to ensure they include sexual orientation, gender identity and gender expression. The company views diversity and inclusion as essential to a good work environment and the achievement of its corporate goals. In 2020, it employed 51% men and 49% women. A gender diversity initiative increased the proportion of women in leadership positions from 28% in 2018 to 32% in 2020. In 2021, QIAGEN exceeded its target of increasing this figure to 33%.
Fostering a diverse and inclusive workforce is central to QIAGEN’s commitment to environmental, social and governance (ESG) standards with which it aims to exceed the requirements of environmental and labor laws. In addition to its workplace goals, QIAGEN is committed to reducing the environmental impact of its business and working with the communities around it in a socially responsible manner.
The Human Rights Campaign Foundation is the educational arm of HRC, America’s largest civil rights organization working for equality for lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people. Bloomberg is a business information company that launched the GEI in 2016.
To learn more about QIAGEN’s commitment to employees, click here.
For more information on the CEI, please visit www.hrc.org/cei, additional information on the GEI is provided at www.bloomberg.com/gei.
QIAGEN NV, a Netherlands-based holding company, is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant and actionable insights. Automation solutions connect them in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in the fields of molecular diagnostics (human health) and life sciences (universities, pharmaceutical R&D and industrial applications, mainly forensic). As of December 31, 2021, QIAGEN employed over 6,000 people in more than 35 locations worldwide. Further information is available at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein regarding QIAGEN’s products, collaboration markets, strategy or results of operations, including, without limitation, its adjusted net sales and results adjusted diluted expected, are forward-looking statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These uncertainties and risks include, but are not limited to, risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability operating results and allocations between customer categories; business development of markets for our products to customers in academia, pharmaceuticals, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competetion; rapid or unexpected technological changes; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, level and timing of customer funding, budgets and other factors); our ability to obtain regulatory approval for our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; QIAGEN’s ability to identify and develop new products and to differentiate and protect our products from competing products; market acceptance of new QIAGEN products and integration of acquired technologies and businesses. For more information, please refer to discussions in reports that QIAGEN has filed with or provided to the United States Securities and Exchange Commission (SEC).